

Carrigent Executive Summary

Carrigent is a biotech company developing CARGO, a next-generation non-viral delivery platform designed to overcome the core limitations of today's gene and cell therapies. Current approaches suffer from high production costs, gene size constraints, and inefficient delivery, all of which limit clinical reach and inflate treatment costs. CARGO addresses these barriers by enabling the targeted, low-dose delivery of large genetic or protein payloads directly to specific cell types, with greater precision, lower toxicity, and reduced immunogenicity.

To complement CARGO, Carrigent is also advancing innovations in viral vector manufacturing, achieving lentiviral titers 3–5x higher for small inserts and >100x for large inserts (6–8kb). This enables the production of more complex constructs at significantly lower cost, expanding what's possible in CAR-T, gene editing, and engineered cell therapies.

We are currently raising a \$2M seed round to complete proof-of-concept for CARGO, optimize platform components, and initiate preclinical development for our first gene therapy asset. Near-term revenues from service work are generating market traction, customer insight, and embedding our technology for long-term partnerships.

With deep domain expertise and disruptive potential, Carrigent is positioned to reshape the future of genetic medicine, making therapies safer, more scalable, and more accessible.